Key points are not available for this paper at this time.
Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
Building similarity graph...
Analyzing shared references across papers
Loading...
Paolo Ghia
Vita-Salute San Raffaele University
Andrzej Pluta
Rzeszów University of Technology
Małgorzata Wach
Medical University of Lublin
Journal of Clinical Oncology
Vita-Salute San Raffaele University
National Health Service
University of New Brunswick
Building similarity graph...
Analyzing shared references across papers
Loading...
Ghia et al. (Wed,) studied this question.
synapsesocial.com/papers/69dbebecc34c3c3eb46841e5 — DOI: https://doi.org/10.1200/jco.19.03355